Blueprint for progress

The approval and launch of the COVID-19 vaccines is a beacon of hope as we enter 2021. Economic activity across markets has started normalizing and we will continue to see stable trends and recovery and expect this momentum to be accelerated, particularly with the rollout of the vaccine.

The generic pharma industry has been focused on ensuring access of medicines to patients during these tough times and has ensured a stable supply chain through the pandemic. The industry has also focused on exploring ways of innovating business models in ways that are more patient-centric. The industry has leveraged technology to deliver information and medicines to patients and physicians in the backdrop of reduced in-person interactions.

The full article was originally published on Express Pharma